Abingworth

News

Abingworth 'will launch $1.5bn fund for co-developed drugs'

Abingworth is reported to be raising $1.5bn for further risk-sharing, royalty-bearing development deals with large pharma groups.

News

Takeda signs deal with UK biotech GammaDelta Therapeutics on...

UK biotech pioneering new type of T cell immunotherapy

News

Andexxa reaches the end of the line in the US

AstraZeneca will voluntarily take its anticoagulant reversal agent Andexxa off the market in the US amid reports of serious clotting side effects.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks